# Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal

> **NCT06176794** · PHASE2 · WITHDRAWN · sponsor: **Sarfez Pharmaceuticals, Inc.**

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Immediate release torsemide 20mg tablet
- **DRUG:** Extended release torsemide 24mg tablet

## Key facts

- **NCT ID:** NCT06176794
- **Lead sponsor:** Sarfez Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-11-15
- **Primary completion:** 2025-03-25
- **Final completion:** 2025-03-25
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Recruitment issues.
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06176794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06176794, "Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06176794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*